UNSPSC 51143400: Combination antimigraine agents

This classification denotes combination drugs that treat primary headache disorders which feature recurrent unilateral pulsatile headaches of types classic (with visible aura neurological symptoms) and type common migraine (without visible aura), headaches commonly called migraines, hence the term ANTIMIGRAINE AGENTS. Typical combination antimigraine agent constituents are acetaminophen, belladonna, caffeine, ergotamine, and naproxen.

UNSPSC 51143400 Combination antimigraine agents is a Class code, but the recent state and local activity under this code shows minimal alignment with the nominal scope. The single recent opportunity posted under the code is Seminole County, Florida's June 2026 IFB for naloxone and safe drug deactivation systems—products used for opioid overdose reversal and controlled drug disposal, not migraine treatment. State and local procurement offices appear to apply this code inconsistently or as a catch-all for pharmaceutical and medical countermeasures beyond its stated therapeutic category. The scope of work being solicited reflects emergency response and community health infrastructure rather than migraine medication procurement.

The geographic activity is limited to Florida based on available records. Seminole County's IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a two-year initial term and one-year renewal option. The procurement required electronic bid submission, drug-free workplace certification, E-Verify compliance, and specific insurance coverage including workers' compensation and commercial general liability. No set-aside designations were specified. The mismatch between the code's migraine-agent classification and the actual procurement of overdose-reversal medication suggests either data-entry error in coding the opportunity or inconsistent taxonomy application by the issuing body. Recent activity in this code is sparse and does not clearly represent a viable procurement category for migraine therapeutics.